Two new enzyme-linked immunosorbent assays (ELISA), one for the measurement of immunoglobulin G (IgG) (Captia Syphilis-G) The enzyme-linked immunosorbent assay (ELISA) for antibody to T. pallidum has been shown to offer several advantages over the current tests (4, 18, 25) : it is simple and rapid, and it gives results that are read objectively.
serum samples from treated patients were reactive in the IgG ELISA, but only 15 samples were reactive in the IgM capture ELISA, which appeared to be as effective as the 19S(IgM) FTA-ABS test in monitoring the effect of treatment. Simultaneous measurement of IgG and IgM antibodies for T. pallidum by the Captia immunoassays appears to be an efficient and simple method for confirming the diagnosis of syphilis as well as for indicating whether active disease is present.
Serological testing for syphilis is an important tool in the prompt and accurate diagnosis of all stages of the disease (27) . In France, a screening combination comprising the Venereal Diseases Research Laboratory (VDRL) test and the Treponema pallidum hemagglutination assay (TPHA) is widely used. The fluorescent treponemal antibody absorption (FTA-ABS) test is often used as a confirmatory test in samples showing reactivity in other assays. Treatment monitoring is currently done by determination of the decline of either anticardiolipin or, less often, antitreponemal immunoglobulin M (IgM) antibodies (8, 10) . Unfortunately, the VDRL test and TPHA combination does not lend itself readily to automation, and the FTA-ABS is laborious and time-consuming.
The enzyme-linked immunosorbent assay (ELISA) for antibody to T. pallidum has been shown to offer several advantages over the current tests (4, 18, 25) : it is simple and rapid, and it gives results that are read objectively.
In the present study, we report an evaluation of two recently introduced ELISA (Captia Syphilis-G and Captia Syphilis-M; Mercia Diagnostics, Guildford, England) to detect IgG and IgM antibodies to treponemes in patients with treated or untreated syphilis.
MATERIALS AND METHODS
Sera. Sera were obtained from specimens submitted to the Diagnostic Laboratory for routine testing and were stored at -70°C until used. A total of 178 serum samples from patients for whom clinical histories could be obtained were included in the study. Of these patients, 96 were untreated. The samples from 63 patients treated for syphilis were collected at various intervals after the start of treatment. Duplicate * Corresponding author. serum samples from nine treated patients were tested. In addition, samples from 10 neonates of mothers who were adequately treated for syphilis, without clinical signs indicative of syphilis, were used. All samples were reactive in the TPHA and the FTA-ABS test.
Serological tests. All sera were tested by the VDRL test (BioMérieux, Marcy l'Etoile, France); the TPHA (Fujirebio, Tokyo, Japan), by the instructions of the manufacturers; the FTA-ABS test (24) ; and the 19S(IgM) FTA-ABS test, after fractionation of the serum by sucrose density gradient ultracentrifugation (8 reaction was stopped by adding 25 ptl of sulfuric acid (2 mol/liter) to each well. Captia Syphilis-M is a capture ELISA procedure using comparable test kits, which include microtitration plates coated with anti-human IgM and the other reagents mentioned above. Microtiter plates coated with anti-human IgM were incubated for 1 h at 37°C with 100 ,ul of serum diluted 1/50 in dilution buffer. After the wells had been emptied and washed with 300 ,uI of wash buffer, the plates were incubated for 1 h with 100 ,ul of tracer complex, diluted 1/20. The tracer complex consisted of T. pallidum antigens, a biotinylated antiaxial filament monoclonal IgM antibody, and streptavidin conjugated with horseradish peroxidase. The wells were again washed, and 100 ,ul of substrate was added. The reaction was stopped after 30 min by adding 25 ,ul of sulfuric acid (2 mol/liter).
Test validation and interpretation were performed as follows. The plates were read on a multiscan reader (Titertek) at 450 nm. The tests results were validated by running negative and low-titer positive kit controls. The run was considered valid if the mean absorbance of the negative control was less than 0.25 and the mean absorbance of the low-titer positive control was more than 1.5 times that of the negative control. The cutoff point between positive and negative was set at the absorbance of the low-titer positive control, according to the manual supplied by the manufacturer. Screen samples showing an absorbance value within about 10% of that of the low-titer positive control were tested again. All sera were screened for rheumatoid factor by a latex agglutination test (Rapitex; Behring Werk, Federal Republic of Germany).
RESULTS
Serum samples from 96 patients with untreated syphilis were tested with the Captia Syphilis assays, and the results were compared with those of the other tests (Table 1 ). All the sera gave positive results in the TPHA and the FTA-ABS test. The IgG ELISA showed sensitivity comparable to that of these tests at all stages of untreated syphilis, except for primary syphilis: two specimens gave negative results, and one was equivocal. The three serum samples gave positive results in the VDRL test, which was equivocal with another serum at this stage. Retesting these samples did not alter the results. In the late latent syphilis, the sensitivity of the Captia Syphilis-G test was higher than that of the VDRL test. The IgM capture ELISA and the 19S(IgM) FTA-ABS test showed comparable sensitivities at all stages except reinfection. With the IgM capture ELISA, the percentage of reactive sera decreased as the stage of syphilis became more advanced. Whereas there were high sensitivities in sera from patients with primary, secondary, and early latent syphilis, sensitivities were lower in sera from patients with late latent syphilis and with reinfection. All samples gave negative results when tested for the presence of rheumatoid factor, except one from a patient with neurosyphilis. The serum of this patient gave a positive result in the IgM capture ELISA but a negative result in the 19S(IgM) FTA-ABS test. detection ofuntreated early infection is very important in the control of the disease. In light of our results, the use of the Captia Syphilis-G assay for screening purposes instead of the present combination of the VDRL test and TPHA, as has been suggested (28), does not appear to be suitable. The ability of the IgG ELISA to detect VDRL-negative infection at other stages of the disease is also important, since a large percentage of cases of untreated late syphilis (45% in our study) may come into in this category. This high sensitivity of the Captia Syphilis-G assay and its excellent specificity (as reported by Young et al. [28] , who studied 1,260 patients with negative serological tests) are ideally suited to confirming the treponemal nature of serum samples preselected on the basis of VDRL test reactivity. A similar conclusion has been reached for another commercially available IgG ELISA, the Bio-EnzaBead test, which could be used as an alternative confirmatory test (2, 11, 23) . In our study, the Captia Syphilis-G assay was reactive with all sera from treated patients. This result confirms that treatment monitoring with the IgG ELISA is not of value, because IgG antibodies to treponemes persist after successful treatment (1) .
The significance of IgM in syphilis in the areas of treatment evaluation, early detection, surveillance, and congenital syphilis has been reported (6, 15, 21, 26) . A reactive treponemal IgM test in untreated patients is proof of active syphilis (9, 12) . Treponeme-specific IgM can most reliably be detected in the 19S(IgM) fraction after its separation from serum. The 19S(IgM) FTA-ABS test, which is highly sensitive and specific for treponemal IgM antibodies in all stages of syphilis, is considered a reference method (9, 12) . However, this assay is time-consuming and technically complicated, making a simpler procedure desirable. The results of our study showed that in early stages of syphilis, it could be replaced by the Captia Syphilis-M assay, which is easier to perform and more economical. As reported previously (4, 22, 26), we observed a decrease in IgM antibody as the stage of syphilis increased. The sensitivity of the IgM capture ELISA was 94% for primary syphilis, 85% for secondary syphilis, and 82% for early latent syphilis, compared with that of the 19S(IgM) FTA-ABS test. These results are similar to recently reported sensitivity values for the Captia Syphilis-M test (5) . In the case of reinfection, however, our study showed that the sensitivity of the IgM capture ELISA was only 62% of that of the 19S(IgM) FTA-ABS test. Lower sensitivity has been observed in reinfections with another IgM capture ELISA by Pedersen et al. (16) . Nonreactive (IgM) FTA-ABS tests with sera from reinfected patients have been also reported (7, 19, 20) . This may have been due to the phenomenon of steric competition, since many workers succeeded in detecting these antibodies after separating IgM and IgG antibodies (7, 13, 19, 20) . Another explanation for this lack of sensitivity might be the fact that a surplus of IgG can inhibit IgM production in vivo (12) . Our study confirms that testing for antitreponemal IgM is useful for detecting active disease early but also that the absence of IgM antibodies to treponemes does not imply that syphilis is absent (8, 16, 22) .
Detection of the IgM antibody is also important for follow-up treatment or in surveillance. Any appreciable decrease in IgM antibodies may be interpreted as evidence oftherapeutic success (8-10, 15, 21) . In our study, the Captia Syphilis-M assay was reactive with only 15 serum samples from 63 treated patients. Therefore, it appears to be as effective as the 19S(IgM) FTA-ABS test in monitoring the effect of treatment response. (16) . In the Captia Syphilis-M assay, a tracer complex is used instead of an IgG class conjugate, which should eliminate the interaction of rheumatoid factor. However, of six serum samples containing rheumatoid factor in our study, two were reactive in the Captia Syphilis-M test but not in the 19S(IgM) FTA-ABS test. This limitation could be overcome by precipitating total serum IgG (13).
In conclusion, the simultaneous measurement of IgG and IgM antibodies for T. pallidum by the Captia immunoassays appears to be an efficient method for confirming the serodiagnosis of syphilis as well as for supplying the investigator with additional information for serological evaluation of the patient and the disease. Compared with the FTA-ABS test, the Captia Syphilis assays have several advantages. The tests can easily be automated, and the use of automatic plate readers eliminates the subjectivity of visual reading and the fatigue and eye strain associated with microscopy. Finally, the simultaneous utilization of the two Captia assays should limit the possibility of false-negative or false-positive results which can be observed when only one test is carried oût.
